Skip to main content
    V

    Vaxcyte Inc (PCVX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $65.27
    -2.28 (-3.38%)

    Market Cap: $11.04B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(11/26)
    Avg Surprise
    -1.93%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-2.14
    Range$-2.68 - $-1.67
    7 analysts
    EPS Revisions
    4
    0
    7d
    4
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-2.16+1.3%
    60d ago$-2.14+0.1%
    30d ago$-2.14+0.1%
    7d ago$-2.14+0.1%
    Current$-2.14
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-2.23
    Range$-3.65 - $-0.18
    7 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-2.23---
    Sep 26EST
    		-$-2.14---
    Jun 26
    Reported Aug 5
    		$-1.97$-1.47-34.01%Miss-61.5%
    Mar 26
    Reported May 6
    		$-2.30$-1.77-29.94%Miss-121.2%
    Dec 25
    Reported Feb 24
    		$-1.80$-1.47-22.45%Miss-76.9%
    Sep 25
    Reported Nov 4
    		$-1.56$-1.24-25.81%Miss-88.0%
    Jun 25
    Reported Aug 6
    		$-1.22$-1.16-5.17%Miss-10.9%
    Mar 25
    Reported May 7
    		$-1.04$-0.97-7.22%Miss-22.4%
    Dec 24
    Reported Feb 25
    		$-1.02$-0.99-2.58%Miss+44.1%
    Sep 24
    Reported Nov 5
    		$-0.83$-0.99+16.16%Beat+8.8%
    Jun 24
    Reported Aug 6
    		$-1.10$-1.00-10.00%Miss-57.1%
    Mar 24
    Reported May 8
    		$-0.85$-1.06+19.81%Beat-21.4%
    Dec 23
    Reported Feb 27
    		$-1.82$-1.07-70.09%Miss-78.4%
    Sep 23
    Reported Nov 6
    		$-0.91$-0.84-8.33%Miss+2.2%
    Jun 23
    Reported Aug 8
    		$-0.70$-0.77+9.09%Beat+12.5%
    Mar 23
    Reported May 8
    		$-0.70$-0.88+20.45%Beat-2.9%
    Dec 22
    Reported Feb 27
    		$-1.02$-0.93-9.68%Miss-85.5%
    Sep 22
    Reported Nov 7
    		$-0.93$-0.85-9.41%Miss-82.4%
    Jun 22
    Reported Aug 8
    		$-0.80$-0.66-21.21%Miss-73.9%
    Mar 22
    Reported May 9
    		$-0.68$-0.66-3.03%Miss-65.9%
    Dec 21
    Reported Feb 28
    		$-0.55$-0.56+1.79%Beat-34.1%
    Sep 21
    Reported Nov 10
    		$-0.51$-0.58+12.07%Beat-24.4%
    Jun 21
    Reported Aug 11
    		$-0.46$-0.53+13.21%Beat+73.3%
    Mar 21
    Reported May 11
    		$-0.41$-0.56+26.79%Beat-41.4%
    Dec 20
    Reported Mar 29
    		$-0.41$-0.54+24.07%Beat+62.0%
    Sep 20
    Reported Nov 12
    		$-0.41$-0.44+6.82%Beat-
    Jun 20
    Reported Aug 12
    		$-1.72$-1.27-35.43%Miss-
    Mar 20
    Reported Jun 15
    		$-0.29N/A+94.06%Beat-
    Dec 19
    Reported Mar 30
    		$-1.08$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-8.55EV/EBITDAN/A
    Price/FCF-10.55xFCF Yield-9.48%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-36.50%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio5.72xQuick Ratio5.72x
    Trading Statistics
    Beta1.23Avg Volume3.39M
    52-Week High$90.7552-Week Low$39.87

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$67.06
    SMA 20$62.21
    SMA 50$60.98
    SMA 200$56.14
    EMA 10$65.96
    EMA 20$63.90
    EMA 50$61.10
    EMA 200$55.03

    MACD

    Line: 2.36Signal: 1.84Hist: 0.52

    ADX

    ADX: 34.4+DI: 39.0-DI: 17.1

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down40.0
    PSAR$90.75

    Bollinger Bands

    Upper Band$74.17
    Lower Band$50.25
    %B Position3844%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    53.7

    Momentum Oscillators

    Stoch %K31.3
    Stoch %D36.2
    Williams %R-72.8
    ROC (10d)16.4%
    Momentum9.22
    CCI (20d)41.5
    MFI (14d)44.2

    Volatility Measures

    ATR (14d)$4.57(7.0%)
    StdDev (20d)5.98
    Hist Vol128.0%(High)

    Volume Flow

    VWAP$66.17
    OBV12.7M
    AD Line-7.3M
    CMF (20d)-0.155

    Volume Metrics

    Avg Vol (20d)3.6M
    Vol Ratio0.7x
    VWMA (20d)$66.17

    Pivot Points

    R3$72.38
    R2$70.79
    R1$69.17
    Pivot Point$67.58
    S1$65.97
    S2$64.38
    S3$62.76

    Advanced Oscillators

    TSI15.95
    Ultimate Osc47.3
    KST100.42

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$14.45M$0
    Cost of Revenue$0$0$-4,989,000$0$0$0N/A$0$0$0$2.95M$0
    Gross Profit$0$0$4.99M$0$0$0N/A$0$0$0$11.50M$0
    Operating Expenses$302.78M$345.85M$274.28M$242.38M$226.22M$180.79M$162.17M$139.92M$152.98M$114.47M$196.68M$113.03M
    R&D$267.85M$312.78M$242.06M$209.93M$194.18M$148.13M$133.61M$116.94M$131.51M$94.59M$104.15M$97.42M
    SG&A$34.92M$33.07M$32.22M$32.45M$32.04M$32.66M$28.55M$22.99M$21.47M$19.89M$17.53M$15.61M
    Operating Income$-302,777,000$-345,850,000$-274,283,000$-242,380,000$-226,219,000$-180,793,000$-162,169,000$-139,924,000$-152,981,000$-114,472,000$-196,676,000$-113,026,000
    Interest Income$25.75M$26.61M$26.45M$29.26M$31.07M$32.94M$36.46M$28.06M$23.81M$21.67M$16.91M$18.50M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-284,302,000$-319,240,000$-246,507,000$-212,830,000$-166,573,000$-140,718,000$-137,080,000$-103,124,000$-128,703,000$-95,020,000$-180,801,000$-92,664,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-284,302,000$-320,622,000$-246,507,000$-212,830,000$-166,573,000$-140,718,000$-137,080,000$-103,124,000$-128,703,000$-95,020,000$-180,801,000$-92,664,000
    EBITDA$-305,313,000$-343,108,000$-265,922,000$-239,156,000$-197,150,000$-173,692,000$-180,429,000$-132,793,000$-158,972,000$-124,586,000$-197,136,000$-123,251,000
    EBIT$-310,057,000$-345,850,000$-272,958,000$-242,089,000$-197,646,000$-173,653,000$-173,538,000$-131,181,000$-152,516,000$-116,686,000$-197,715,000$-111,159,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PCVX

    News

    Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program Advances

    Vaxcyte Inc. (PCVX) has achieved significant stock gains, exceeding 100% since October 2025, driven by advancements in its pneumococcal vaccine program. The company's lead candidate, VAX-31...

    RTTNews•10/16/26•Bullish

    Vaxcyte (PCVX), What Is Behind The Fresh Attention?

    Vaxcyte (PCVX) has gained significant attention after its VAX-31 pneumococcal vaccine candidate successfully met all co-primary immunogenicity endpoints in the Phase 3 OPUS-1 trial...

    Simply Wall Street•10/15/26•Bullish

    Vaxcyte Stock In Focus After Phase 3 Vaccine Trial Success

    Vaxcyte (NasdaqGS:PCVX) announced positive Phase 3 trial results for its 31-valent pneumococcal vaccine, VAX-31...

    Simply Wall Street•10/14/26•Bullish

    Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

    Wall Street analysts project a potential 75.6% upside for Vaxcyte (PCVX), with a mean price target of $117.3. While consensus price targets can be misleading due to analyst optimism...

    Yahoo Finance•10/14/26•Bullish

    How Vaxcyte Inc. (PCVX) Affects Rotational Strategy Timing

    This article analyzes Vaxcyte Inc. (PCVX) focusing on its impact on rotational strategy timing. It highlights weak near-term sentiment that could precede shifts in mid and long-term outlook...

    Stock Traders Daily•10/13/26•Bearish

    PCVX Valuation and Fair Value

    P/E
    -8.6x
    P/FCF
    -10.5x
    P/B
    3.4x
    See GNG's fair value

    PCVX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -36.5%
    FCF yield
    -9.5%

    PCVX Competitors

    CompanyTicker
    Fresenius Medical Care CorporationFMS
    Universal Health Services IncUHS
    Elanco Animal HealthELAN
    Molina Healthcare IncMOH
    Repligen CorporationRGEN
    Dr. Reddy’s Laboratories Ltd ADRRDY
    Bio-Techne CorpTECH
    Oscar Health IncOSCR

    Sector: Healthcare

    PCVX Analyst Ratings

    Consensus
    Buy
    Analysts
    11
    Strong Buy
    1
    Buy
    9
    Hold
    1
    Sell
    0
    Strong Sell
    0

    PCVX Bull Case vs Bear Case

    Bull case

    • 90.9% of PCVX's analyst ratings are Buy or Strong Buy.

    Bear case

    • PCVX beat EPS estimates in 12.5% of its last 8 reported quarters.

    PCVX Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)
    Average surprise
    -13.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-2.14
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    4 up, 0 down

    Frequently Asked Questions About PCVX

    Does PCVX pay dividends?

    Vaxcyte Inc (PCVX) does not currently pay a regular dividend.

    What is PCVX's market cap?

    Vaxcyte Inc (PCVX) has a market capitalization of $11.04B with a current stock price of $65.27.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In